The goal of the annual US-Japan cellular and gene therapy conference is to exchange ideas on cutting edge and diverse areas of biomedical research, and enhance opportunities for collaborations among scientists from the US and Japan. The conference is jointly supported by the Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration (FDA); and the Ministry of Education, Culture, Sports, Science and Technology, Japan under the US-Japan Cooperative Research Program. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat)/Cas9 (CRISPR associated protein-9) is currently most versatile and precise method of gene manipulation. Six speakers from the US and five from Japan will discuss the advances and potential applications of CRISPR/Cas9-based genome editing system. The FDA speaker will present US regulatory perspective of gene editing technologies.
Members of the public may attend in person or via webinar. More information is available from the FDA website.